HR Execs on the Move

Celsis Inc

www.celsis.com

 
Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.celsis.com
  • 600 W Chicago Ave
    Chicago, IL USA 60654
  • Phone: 312.476.1200

Executives

Name Title Contact Details

Similar Companies

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.

Rockland Immunochemicals

Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LAVA Therapeutics

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

MeMed

MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.